Analysts' Actions: BMY GPS KORS MRK SCHW

NEW YORK (TheStreet) -- CHANGE IN RATINGS

Bristol-Myers ( BMY) was downgraded to neutral at Bank of America/Merrill Lynch. The upside potential does not justify a buy rating, though the dividend yield and pipeline are attractive, BofA/Merrill said. Estimates through 2014 were increased, price target is $39.

Cloud Peak Energy ( CLD) was upgraded at Goldman Sachs to buy. The company should benefit from rising PRB coal/natural gas prices, Goldman said. Price target is now $21.

Consol Energy ( CNX) was downgraded at Goldman Sachs to neutral. Still see positive catalysts, but believe that others have more upside, Goldman said. Price target is now $36.

Cyberonics ( CYBX) was upgraded at Lazard Capital Markets to buy. A proprietary survey showed that sales reps were not using inappropriate sales tactics, making the recent pullback a buying opportunity, Lazard Capital Markets said. Estimates through 2014 were raised, $57 price target.

Dean Foods ( DF) was upgraded at KeyBanc to buy. The company's structural transition to a fluid milk pure play will drive cost savings that aren't currently realized in the stock price, KeyBanc said. Price target is $21.

Exlservice ( EXLS) was downgraded at Needham from buy to hold. Company is facing increased competition, Needham said.

Fifth & Pacific ( FNP) was initiated with a buy rating at Sterne Agee. The company is the top specialty retailer pick given growth prospects and misunderstood fundamentals, Sterne Agee said. Price target is $26.

Foster Wheeler ( FWLT) was downgraded at Stifel Nicolaus from buy to hold. Company faces growth headwinds and lacks potential near-term catalysts, Stifel Nicolaus said.

Gap ( GPS) was initiated with a sell rating at Sterne Agee. Structural headwinds, including tough compares and inventory levels, will weigh on margins, Sterne Agee said. Price target is $29.

Michael Kors ( KORS) was initiated with a neutral rating at Sterne Agee. Margins at the company could be nearing the end of the runway, Sterne Agee said. Price target is $63.

McDermott ( MDR) was downgraded at KeyBanc to hold. The company's cost position as it transitions to deep-water work is a concern, KeyBanc said. There is a risk to margins and stimates were lowered through 2014, Keybanc added.

Medivation ( MDVN) was initiated with a buy rating at Needham. Xtandi is rapidly gaining market share for the treatment of prostate cancer, Needham said.

Merck ( MRK) was upgraded to buy at Bank of America/Merrill Lynch. Low expectations, a cheap valuation and dividend yield make this stock attractive, BofA/Merrill said. Estimates through 2015 were increased, price target is $47.

Micron ( MU) was downgraded at Lazard Capital Markets to neutral. With DRAM strength set to taper off, consensus estimates are too bullish and the stock is expensive, Lazard Capital Markets said.

Radian Group ( RDN) was upgraded at Keefe, Bruyette & Woods to outperform following Radian's capital raise. Estimates for 2014 and 2015 were introduced showing the company returning to sustained operating profitability, KBW said. New price target is $12.

Charles Schwab ( SCHW) was upgraded at Bernstein to outperform. The company will benefit from rising interest rates and a late cycle rebound in retail activity, Bernstein said. 2013 estimates were increased and the new price target is $23.

STOCK COMMENTS/EPS CHANGES

Bank of New York Mellon ( BK) numbers were increased at Jefferies. Shares are now seen reaching $29. Estimates also increased, given higher equity returns, Jefferies said. Hold rating.

Myriad Genetics ( MYGN) numbers were cut at Credit Suisse. Shares are now seen reaching $28. Estimates were also reduced, given lower Medicare reimbursement rates, Credit Suisse said. Neutral rating.

Northern Trust ( NTRS) numbers were increased at Jefferies through 2014. Company is leveraged to higher equity prices and currency trading, Jefferies said. Hold rating.

The Fresh Market estimates ( TFM) estimates, target were reduced at UBS. Estimates for the fourth quarter and through 2014 were cut, based on commentary from other high-end food retailers and upcoming tough comparisons, UBS said. Maintain Buy rating, new $60 price target.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.

More from Stocks

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain